UAB researchers leading way on drug regimen battling cystic fibrosis
A triple combination drug has been shown to be effective in improving lung function for the majority of patients with cystic fibrosis.   The new therapy can provide therapeutic benefits for 90 percent of all patients with the disease, according to findings published in the New England Journal of Medicine. Researchers from UAB report the medication, which combines an experimental compound known as VX-659 with two existing medicati ons, tezacaftor and ivacaftor, improved lung function by more than… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 19, 2018 Category: American Health Authors: Tyler Patchen Source Type: news

Triple Combo Regimens May Address Cause of Cystic Fibrosis
FRIDAY, Oct. 19, 2018 -- Triple therapy with VX-659 or VX-445 combined with tezacaftor-ivacaftor shows promise for the treatment of adult patients with cystic fibrosis who have mutations in the cystic fibrosis transmembrane conductance regulator... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2018 Category: Pharmaceuticals Source Type: news

3-Drug Therapy Might Be Cystic Fibrosis Advance
In what researchers call “a breakthrough,” two clinical trials have found that two different three-drug treatment plans could help 90 percent of people with cystic fibrosis. “It’s not a cure,” said one of the lead researchers. “But it could be game-changing.” (Source: WebMD Health)
Source: WebMD Health - October 18, 2018 Category: Consumer Health News Source Type: news

3 - Drug Therapy Might Be Cystic Fibrosis ‘ Breakthrough ’
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 18, 2018 Category: Respiratory Medicine Tags: Family Medicine, Pharmacy, Pulmonology, Research, News, Source Type: news

' Major Breakthrough' in Cystic Fibrosis Treatment'Major Breakthrough' in Cystic Fibrosis Treatment
Adding a third drug to modulate the CFTR protein improved respiratory function and reduced sweat chloride concentrations in most patients with cystic fibrosis. Phase 3 trials are ongoing.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 18, 2018 Category: Primary Care Tags: Pulmonary Medicine News Source Type: news

3-Drug Therapy Might Be Cystic Fibrosis'Breakthrough '
THURSDAY, Oct. 18, 2018 -- In what researchers are calling a " breakthrough, " two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis. The trials were short-term,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 18, 2018 Category: General Medicine Source Type: news

A day in the life of a 10-year-old patient at Alder Hey
She has cystic fibrosis and shared a day in her life to show what it's like for her. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 13, 2018 Category: Consumer Health News Source Type: news

I'm Drowning
(MedPage Today) -- A researcher-patient's plea for broader inclusion in cystic fibrosis trials (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 11, 2018 Category: American Health Source Type: news

Scientists reveal new cystic fibrosis treatments work best in inflamed airways
(University of North Carolina Health Care) A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate the efficacy of these drugs under inflammatory conditions relevant to CF airways. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 11, 2018 Category: Biology Source Type: news

Carriers of cystic fibrosis may be at greater risk for allergic bronchopulmonary aspergillosis
Tue, 10/09/2018 - 11:45News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 9, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Cystic fibrosis sufferer lifts one million kilograms in 22 hours
Josh Llewellyn-Jones completes the "crazy" challenge to inspire others living with the disorder. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 1, 2018 Category: Consumer Health News Source Type: news

Interventions for the eradication of meticillinresistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
This review concluded that whilst early eradication of respiratory MRSA in cystic fibrosis with oral trimethoprim and sulfamethoxazole combined with rifampicin is possible, the evidence is of low quality to justify use. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 28, 2018 Category: Consumer Health News Source Type: news

Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 27, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Nontuberculous Mycobacteria in Cystic Fibrosis Nontuberculous Mycobacteria in Cystic Fibrosis
In this article, the diagnosis, treatment, and impact of nontuberculous mycobacteria infection among patients with cystic fibrosis is discussed.Seminars in Respiratory and Critical Care Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Insuring patient access and affordability for treatments for rare and ultra-rare diseases
(American College of Medical Genetics and Genomics) The last decade has seen tremendous progress in the development of new drugs for patients with genetic disorders, including Cystic Fibrosis, many lysosomal storage disorders (Gaucher disease, Fabry disease and others) and most recently, Duchenne Muscular Dystrophy and Spinal Muscular Atrophy (SMA). The American College of Medical Genetics and Genomics (ACMG) is concerned with the staggering projected cost of these new treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 7, 2018 Category: International Medicine & Public Health Source Type: news

Claire Wineland, who chronicled cystic fibrosis, dies at 21
Claire Wineland used social media platforms to speak about the difficult details of her life and spread awareness about the disease (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 4, 2018 Category: Consumer Health News Source Type: news

Claire Wineland, inspirational speaker and social media star, dies one week after lung transplant
Cystic fibrosis did not define Claire Wineland. She did. (Source: CNN.com - Health)
Source: CNN.com - Health - September 4, 2018 Category: Consumer Health News Source Type: news

Claire Wineland: Cystic fibrosis activist dies at 21
Claire Wineland made a name for herself writing and speaking about her life with the disease. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 4, 2018 Category: Consumer Health News Source Type: news

A lung transplant gave her hope for a longer life; now her family prays for 'another miracle'
Claire Wineland, who has cystic fibrosis, needed a double-lung transplant to save her life. But she had a stroke and is now in a medically induced coma. (Source: CNN.com - Health)
Source: CNN.com - Health - August 29, 2018 Category: Consumer Health News Source Type: news

Cystic fibrosis mothers' plea over 'life-changing' drug
Two mothers call on a drug firm and ministers to reach a deal over a 'life-changing' treatment. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 28, 2018 Category: Consumer Health News Source Type: news

Cystic fibrosis mum's drug plea for 'deserving' daughter
Ivy, aged three, has cystic fibrosis and her mum wants a £100,000-a-year to help control Ivy's condition. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 28, 2018 Category: Consumer Health News Source Type: news

Enzyme ducts in the pancreas are formed like rivers
(University of Copenhagen The Faculty of Health and Medical Sciences) With methods used to analyse road systems and rivers researchers from the University of Copenhagen have studied the formation of the pancreas' network of ducts transporting digestive enzymes in mice. The network resembles the structure of road networks and the formation of rivers. The new results can help the researchers gain a better understanding of disorders like cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 27, 2018 Category: International Medicine & Public Health Source Type: news

Africa:How an App Is Helping to Collect Genetic Data in Ethiopia and Ghana
[The Conversation Africa] Genetic technologies are poised to change the world. Want to eradicate a human disease such as cystic fibrosis or improve a person's ability to run impossible distances or lift unimaginable weights? This may be possible in the future by using something called CRISPR to edit an organism's genetic makeup. How about rapidly sequencing a newborn's genome, similar to an early scene in the 1997 movie Gattaca? Next-generation sequencing may make this fiction a reality. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 24, 2018 Category: African Health Source Type: news

Madden Launches DartCF
Dean Madden, Professor of Biochemistry and Cell Biology and Director of the COBRE Institute for Biomolecular Targeting, has received a new NIH program project award to establish the Dartmouth Cystic Fibrosis Research Center (DartCF). This collaborative effort supported by the National Institute of Diabetes and Digestive and Kidney Diseases will […] Read More (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - August 17, 2018 Category: Hospital Management Authors: Heather Smith Tags: News Source Type: news

Electromed touts SmartVest non-cystic fybrosis bronchiectasis study data
Electromed (NSDQ:ELMD) today released results from an independent clinical study exploring the use of high frequency chest wall oscillation therapy with its SmartVest, touting that it significantly reduced severe exacerbations and hospitalizations for non-cystic fibrosis bronchiectasis patients. Findings from the study were presented at the World Bronchiectasis Conference in Washington D.C., the New Prague, Minn.-based company said. “Preventing exacerbations and maintaining pulmonary function is vital to the health and well-being of bronchiectasis patients. This independent study builds on previously publis...
Source: Mass Device - August 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Electromed Source Type: news

Vertex cystic fibrosis drug gets expanded approval for use in infants
U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months. (Source: Reuters: Health)
Source: Reuters: Health - August 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Cystic fibrosis boy, 8, urges firm to lower Orkambi drug price
Luis Walker, 8, wrote to Vertex Pharmaceuticals saying Orkambi would make him "feel much better". (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 15, 2018 Category: Consumer Health News Source Type: news

FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to & lt;24 Months with Certain Mutations in the CFTR Gene
BOSTON--(BUSINESS WIRE)--Aug. 15, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 15, 2018 Category: Drugs & Pharmacology Source Type: news

VIDEO – Taking on Cystic Fibrosis: A Student Story
Dartmouth College undergraduate Sam Neff D '21 fights cystic fibrosis (CF) every day by following a strict treatment regimen, by contributing to CF research in Geisel’s Lung Biology Center, and by participating in a clinical trial at Dartmouth-Hitchcock. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - August 14, 2018 Category: Hospital Management Authors: Jennifer Durgin Tags: Multimedia News Research Video cystic fibrosis Dartmouth undergraduate Home-feature Interaction student research Source Type: news

NICE, Vertex continue to spar over drug prices
The U.K.'s National Institute for Health and Care Excellence (NICE) has suspended its review of Vertex's Symkevi for treating cystic fibrosis patients who are homozygous for the F508del mutation, after the biotech did not provide evidence for the agency's appraisal. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 13, 2018 Category: Pharmaceuticals Source Type: news

Ambitious 'Human Cell Atlas' Aims To Catalog Every Type Of Cell In The Body
Already the project has revealed a previously unknown type of cell in the windpipe that might play a role in cystic fibrosis — and lead to a new treatment, scientists say.(Image credit: Casey Atkins/Broad Institute) (Source: NPR Health and Science)
Source: NPR Health and Science - August 13, 2018 Category: Consumer Health News Authors: Karen Weintraub Source Type: news

Research shows that cystic fibrosis impacts growth in the womb
(University of Liverpool) New research, published in Thorax, funded by the Cystic Fibrosis Trust has shown that babies with cystic fibrosis (CF) are born weighing less than babies without the condition, even allowing that they are more likely to be born prematurely. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2018 Category: International Medicine & Public Health Source Type: news

Finally, a potential new approach against KRAS-driven lung cancer
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center and M.D. Anderson Cancer Center study shows KRAS-driven lung cancers are also marked by high levels of 'gel-forming mucins,' as seen in some forms of asthma, chronic obstructive pulmonary disease and cystic fibrosis. The study, published Aug. 9 in the journal JCI Insight, also pinpoints a cause of increased mucin production, namely the gene MUC5AC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2018 Category: Cancer & Oncology Source Type: news

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). (Source: World Pharma News)
Source: World Pharma News - August 7, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news

Celtaxsys Cystic Fibrosis Drug Reduces Key Symptom in Mid-Stage Study Celtaxsys Cystic Fibrosis Drug Reduces Key Symptom in Mid-Stage Study
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Research shows that cystic fibrosis impacts growth in the womb
(University of Liverpool) New research, published in Thorax, funded by the Cystic Fibrosis Trust has shown that babies with cystic fibrosis (CF) are born weighing less than babies without the condition, even allowing that they are more likely to be born prematurely. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2018 Category: International Medicine & Public Health Source Type: news

Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. (Source: Reuters: Health)
Source: Reuters: Health - August 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New lung cell type discovered
(Harvard Medical School) In separate studies published online in Nature on Aug. 1, two independent research teams report the discovery of a new, rare type of cell in the human airway. These cells appear to be the primary source of activity of the CFTR gene, mutations to which cause cystic fibrosis, a multiorgan disease that affects more than 70,000 people worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2018 Category: International Medicine & Public Health Source Type: news

New Lung Cell Identified
The cell type was discovered via single-cell RNA sequencing of thousands of cells in mouse and human airways and may play a role in cystic fibrosis. (Source: The Scientist)
Source: The Scientist - August 1, 2018 Category: Science Tags: News & Opinion Source Type: news

EMA Panel Backs Tezacaftor, Ivacaftor Combo for CF EMA Panel Backs Tezacaftor, Ivacaftor Combo for CF
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended Symkevi for patients aged 12 years and older with cystic fibrosis (CF).International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

What Causes School Failure?
Discussion “Literacy is traditionally meant as the ability to read and write. The modern term’s meaning has been expanded to include the ability to use language, numbers, images, computers, and other basic means to understand, communicate, gain useful knowledge, solve mathematical problems and use the dominant symbol systems of a culture.” The earliest written communication was in 3500-3000 BCE, with the earliest alphabet being from 1200-750 BCE. Although the percentage of the world’s adult literacy rate is increasing each decade by ~5%, “…from 55.7 per cent in 1950 to 86.2 per cent in...
Source: PediatricEducation.org - July 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Toronto stands out for excellence in cystic fibrosis care in North America
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - July 27, 2018 Category: Hospital Management Tags: Hospital News Source Type: news

Recent Advances in Allergic Bronchopulmonary Aspergillosis Complicating Cystic Fibrosis
Wednesday, July 18, 2018 - 13:02Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Bullying and mental health amongst Australian children and young people with cystic fibrosis - Branch-Smith C, Shaw T, Lin A, Runions K, Payne D, Nguyen R, Hugo H, Balding L, Cross D.
Currently, there is little research investigating how schools can support the mental health and social development of young people with cystic fibrosis (CF), given their heightened risk of mental illness. Few studies have examined the relationship between ... (Source: SafetyLit)
Source: SafetyLit - July 17, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Technique may improve lung delivery of bacteria-killing phage
(Georgia Institute of Technology) A new delivery system for bacteriophages--viruses that selectively attack harmful bacteria--could help give doctors a new way to battle lung infections that threaten older patients and people with cystic fibrosis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 16, 2018 Category: Infectious Diseases Source Type: news

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
This draft guidance sets out an antimicrobial prescribing strategy for managing and preventing an acute exacerbation of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance. A 3-page visual summary of the recommendations is included. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 12, 2018 Category: Consumer Health News Source Type: news

Cystic Fibrosis
Title: Cystic FibrosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/6/2018 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - July 6, 2018 Category: Respiratory Medicine Source Type: news

Postdoctoral Fellow: Comparative genomics and metagenomic approaches in patients with cystic fibrosis colonized with Aspergillus fumigatus and treated with triazoles.
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 5, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news